The present invention belongs to the field of cancer therapy and relates to a composition or product comprising at least one retinoid compound, at least one arsenic compound and at least one proteasome inhibitor, for use in the treatment of acute myeloid leukemia (AML) where the tumor cells are positive for the FLT3-ITD mutation.

The present invention belongs to the field of cancer therapy and relates to a composition or product comprising at least one retinoid compound, at least one arsenic compound and at least one proteasome inhibitor, for use in the treatment of acute myeloid leukemia (AML) where the tumor cells are positive for the FLT3-ITD mutation.

The presently disclosed subject matter provides nanoparticles comprising bortezomib encapsulated in a non-water-soluble polymer matrix in a form of a bortezomib-tannic acid complex; methods for preparing the nanoparticle; and use of the nanoparticles for treating liver cancer.

An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.

An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.

[Problem] The present invention addresses the problem of developing a catalyst compound which has blood-brain barrier penetration properties and enables the oxygenation of amyloids in a body upon being irradiated with light from the outside of the body and providing a prophylactic and therapeutic agent for amyloid-related diseases using the catalyst compound.

[Solution] It is found that a compound having such a framework that an azobenzene-like structure and boron together form a complex is useful as a novel biocatalyst which can selectively oxygenate an amyloid and can prevent the aggregation of the amyloid upon being irradiated with light while significantly reducing the molecular weight of the amyloid. It is also found that the compound can exhibit an oxygenation activity upon the irradiation with light having a longer wavelength which has high tissue penetration properties and has excellent blood-brain barrier penetration properties.

The present disclosure provides an elastase inhibitor prodrug and use thereof, being a compound of formula I or a pharmaceutically acceptable salt, ester, isomer or solvate thereof, prodrugs or isotopically labeled compound. Compared with the compound 52 (control example) in WO 2018/175173 A1, the compound disclosed herein has the advantages of high pulmonary exposure and long half-life. The prodrugs of the present disclosure significantly increase the concentration and residence time of the active compound (control example) in the lungs with significant improvements in pharmacokinetics in vivo compared to the control example.

##STR00001##

The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.

The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.

The present invention relates to compositions and methods for enhancing the efficacy of drug compounds. The subject invention utilizes an adjuvant composition comprising of one or more microbial-produced biosurfactants and/or isoforms thereof to enhance bioavailability, stability, and localization of the drugs in a subject, to reduce the total dosage that is required, and to prolong the pre-administration stability of the drugs.